NCT05228249View on ClinicalTrials.gov

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2023

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2027

Conditions
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory Primary Mediastinal (Thymic) Large B-Cell LymphomaRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo peripheral blood ASCT

DRUG

Carmustine

Given IV

DRUG

Cytarabine

Given IV

DRUG

Etoposide

Given IV

BIOLOGICAL

Loncastuximab Tesirine

Given IV

DRUG

Melphalan

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

ADC Therapeutics
All Listed Sponsors
collaborator

ADC Therapeutics

UNKNOWN

lead

Fred Hutchinson Cancer Center

OTHER